Jump Financial LLC Sells 50,793 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Jump Financial LLC decreased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 82.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,760 shares of the company's stock after selling 50,793 shares during the period. Jump Financial LLC's holdings in Twist Bioscience were worth $500,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Stifel Financial Corp raised its position in Twist Bioscience by 11.8% in the 3rd quarter. Stifel Financial Corp now owns 6,967 shares of the company's stock valued at $315,000 after buying an additional 734 shares during the last quarter. Barclays PLC lifted its position in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after purchasing an additional 104,420 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience during the third quarter valued at about $34,000. Franklin Resources Inc. increased its stake in Twist Bioscience by 3.4% in the 3rd quarter. Franklin Resources Inc. now owns 252,064 shares of the company's stock valued at $11,756,000 after buying an additional 8,308 shares during the last quarter. Finally, Beaird Harris Wealth Management LLC bought a new position in shares of Twist Bioscience during the 3rd quarter worth approximately $95,000.

Insider Buying and Selling

In related news, SVP Paula Green sold 1,259 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $62,131.65. Following the transaction, the senior vice president now directly owns 132,014 shares in the company, valued at approximately $6,514,890.90. This represents a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Patrick John Finn sold 2,058 shares of the business's stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the transaction, the chief operating officer now directly owns 265,460 shares of the company's stock, valued at approximately $10,615,745.40. This represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,432 shares of company stock valued at $1,038,170. Company insiders own 3.01% of the company's stock.

Twist Bioscience Stock Performance

Twist Bioscience stock traded down $0.21 during mid-day trading on Monday, reaching $39.90. The company's stock had a trading volume of 798,848 shares, compared to its average volume of 980,105. The company has a market capitalization of $2.38 billion, a P/E ratio of -11.80 and a beta of 2.34. The firm's fifty day moving average price is $39.67 and its two-hundred day moving average price is $44.29. Twist Bioscience Co. has a 12-month low of $30.32 and a 12-month high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. During the same quarter in the prior year, the firm posted ($0.75) EPS. The firm's quarterly revenue was up 24.1% on a year-over-year basis. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on TWST. Robert W. Baird increased their price target on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, February 4th. Guggenheim set a $50.00 target price on Twist Bioscience in a research note on Friday, March 28th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Barclays lowered their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Finally, JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Twist Bioscience has an average rating of "Moderate Buy" and an average price target of $52.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.